WFA Asset Management’s Alnylam Pharmaceuticals ALNY Stock Holding History

WFA Asset Management’s Portfolio ALNY Stock Details ALNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	$3.85K	Hold	14	–	–	﹤0.01%	173
2025 Q2	$3.4K	Hold	14	–	–	﹤0.01%	184
2025 Q1	$2.09K	Hold	14	–	–	﹤0.01%	213
2024 Q4	$3.29K	Hold	14	–	–	﹤0.01%	202
2024 Q3	$3.85K	Hold	14	–	–	﹤0.01%	174
2024 Q2	$3.4K	Hold	14	–	–	﹤0.01%	185
2024 Q1	$2.09K	Hold	14	–	–	﹤0.01%	214
2023 Q4	$2.68K	Hold	14	–	–	﹤0.01%	201
2023 Q3	$2.48K	Hold	14	–	–	﹤0.01%	212
2023 Q2	$2.66K	Hold	14	–	–	﹤0.01%	214
2023 Q1	$2.81K	Hold	14	–	–	﹤0.01%	214
2022 Q4	$3.33K	Hold	14	–	–	﹤0.01%	194
2022 Q3	$2.8K	Hold	14	–	–	﹤0.01%	212
2022 Q2	$2.04K	Hold	14	–	–	﹤0.01%	204
2022 Q1	$2.29K	Hold	14	–	–	﹤0.01%	188
2021 Q4	$2.38K	Buy	+14	New	+$2.6K	﹤0.01%	171

Other funds holding ALNY

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

WFA Asset Management's ALNY Position: Q3 2025 in Review

WFA Asset Management held its Alnylam Pharmaceuticals (ALNY) position steady in Q3 2025 at 14 shares worth $3.85K. The position accounts for ﹤0.01% of the portfolio, ranked #173.

WFA Asset Management first reported a position in ALNY in Q4 2021 and has held it in 16 quarters since. 822 funds tracked by Wall St. Rank hold ALNY as of Q3 2025.

WFA Asset Management held 14 shares of Alnylam Pharmaceuticals worth $3.85K as of Q3 2025.
WFA Asset Management left its Alnylam Pharmaceuticals share count unchanged in Q3 2025.
Alnylam Pharmaceuticals made up ﹤0.01% of WFA Asset Management's portfolio in Q3 2025, its #173 holding.
WFA Asset Management first reported a position in Alnylam Pharmaceuticals in Q4 2021 and has held it in 16 quarters since.
822 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q3 2025.

Based on WFA Asset Management's 13F filing for Q3 2025, filed 30 Oct 2025.